Level B· Emerging clinical evidence with positive signalsRandomized Controlled TrialPubMedOpen access

Effect of intrabronchial administration of autologous adipose-derived mesenchymal stem cells on severe equine asthma.

Adamič N., Prpar Mihevc S., Blagus R., Kramarič P., Krapež U., Majdič G.

Randomized Controlled Trial with a reported sample of 10 on Chronic Inflammation, published in Stem Cell Res Ther (2022) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
Stem Cell Res Ther (2022)
Country
England
Reported sample size
10
Source database
PubMed
PMID
35063028
PMCID
PMC8777441
DOI
10.1186/s13287-022-02704-7
Citations
8

Abstract (original English)

Background Severe equine asthma (SEA) is a common chronic respiratory disease and a significant health and well-being problem in horses. Current therapeutic strategies improve pulmonary function and clinical signs in some horses, but in the long-term, return to full athletic function appears to be rare. The aim of this study was to assess the safety and the effect of intrabronchial administration of adipose-derived mesenchymal stem cells (AD-MSC) on pulmonary inflammatory and clinical parameters in horses with SEA. Methods This was a randomized controlled trial. Twenty adult horses diagnosed with SEA were randomly divided into two groups (n = 10), and treated either with a single intrabronchial application of autologous AD-MSC or oral dexamethasone for three weeks. A targeted clinical examination with determination of clinical score, maximal change in pleural pressure during the breathing cycle, and an endoscopic examination of the airways were performed at baseline and three weeks after treatment. Bronchoalveolar lavage fluid was analyzed cytologically, and IL-1β, IL-4, IL-8, IL-17, TNFα and IFNγ mRNA and protein concentrations were measured at baseline and three weeks. The horses were then monitored over one year for recurrence of SEA. A non-inferiority analysis and a linear mixed-effects model were performed to assess differences between treatments. Results The non-inferiori

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
AnimalsAsthmaBronchoalveolar Lavage FluidHorse DiseasesHorsesMesenchymal Stem CellsTransplantation, Autologous

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research